AbCellera Biologics (ABCL) Gross Profit (2021 - 2023)

AbCellera Biologics' Gross Profit history runs 3 years deep, the most recent figure standing at $9.2 million for Q4 2023.

• Quarterly Gross Profit fell 54.21% year-over-year to $9.2 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $38.0 million (down 90.93% YoY) and the FY2024 annual result came in at $28.8 million, down 24.17% from the prior year.
• Gross Profit was $9.2 million for Q4 2023 at AbCellera Biologics, up from $6.6 million in the prior quarter.
• Across five years, Gross Profit topped out at $271.9 million in Q1 2022 and bottomed at $5.5 million in Q3 2021.
• A 3-year average of $65.6 million and a median of $22.0 million in 2021 frame the typical range for Gross Profit.
• Annual changes were most pronounced in 2022 — Gross Profit jumped 1468.32% — and 2023, when it tumbled 95.52%.
• AbCellera Biologics' Gross Profit stood at $117.4 million in 2021, then slumped by 82.93% to $20.0 million in 2022, then slumped by 54.21% to $9.2 million in 2023.
• Business Quant data shows ABCL's Gross Profit at $9.2 million in Q4 2023, $6.6 million in Q3 2023, and $10.1 million in Q2 2023.